Venlo, the Netherlands, April 24, 2024 (GLOBE NEWSWIRE) — QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAseq xHYB Mycobacterium tuberculosis Panel for research use, a new tool in the fight against tuberculosis (TB), the world’s leading infectious disease killer.
Building on QIAGEN’s ongoing efforts to support global TB management and control, which include the leading diagnostics test QuantiFERON-TB Gold Plus, the new panel enables culture-free whole genome sequencing (WGS) directly from samples such as sputum or cerebrospinal fluid. This innovation significantly reduces the time to result and enables real-time epidemiology of TB outbreaks, addressing a critical need in the field of TB surveillance and control.
The QIAseq xHYB Mycobacterium tuberculosis Panel represents a major advancement in solving the problem of bacterial WGS from complex host samples, using next-generation sequencing (NGS). It is designed against the seven major lineages of TB, covering the full breadth of diversity. By eliminating the need for a 4-to-6-week bacterial culture, the panel significantly accelerates the process of obtaining results.
“The introduction of the QIAseq xHYB Mycobacterium tuberculosis Panel reflects our ongoing commitment to address global health challenges like TB and antimicrobial resistance,” said Nitin Sood, Vice President, Head of the Life Sciences Business Area at QIAGEN. “This innovative panel not only streamlines the workflow for healthcare professionals and researchers but also enables the real-time tracking of TB outbreaks, a crucial aspect in combating the spread of this devastating disease and managing the growing threat of drug-resistant TB.”
“Innovative aspects of this workflow are the whole genome analysis from clinical samples, avoidance of the culturing delay, and inclusion of genetic diversity,” stated Daniela Maria Cirillo, MD, PhD, Head of Emerging Bacterial Pathogens Unit at IRCCS San Raffaele Scientific Institute, Milan, Italy.
The QIAseq xHYB Mycobacterium tuberculosis Panel also plays a vital role in the detection and management of antimicrobial resistance (AMR), a growing concern in TB treatment. The panel covers all AMR-related genes, allowing for the identification of resistant TB strains, including multidrug-resistant tuberculosis (MDR-TB), which is caused by bacteria that do not respond to the most effective first-line TB drugs.
Surveillance of TB, including drug-resistant strains which occur in around 4% of all TB cases[1], helps track the emergence and spread of resistance. This provides essential information for updating treatment guidelines and spurs research and development efforts focused on new TB treatments and diagnostic methods, ultimately improving patient outcomes.
TB is a contagious bacterial infection, primarily spread by the coughing of patients with the active pulmonary form of the disease. The WHO estimated that there were more than 10 million new cases of active TB worldwide and 1.3 million deaths in 2022.
QIAGEN is committed to supporting TB management worldwide. Its leading diagnostics solution, QuantiFERON-TB Gold Plus, accurately detects latent TB infection by identifying interferon-gamma released by T-cells in response to TB-specific antigens. This one-visit test outperforms the century-old, two-visit TB skin test (TST). Over 100 million QuantiFERON-TB tests have been used worldwide to detect TB, and over 1,500 studies have been published using this test. One in four people worldwide are believed to have latent TB infections, with 5-10% of them expected at some point to develop active TB. The CDC and WHO endorse the use of QuantiFERON-TB Gold Plus to combat the global TB epidemic.
QIAGEN will showcase the QIAseq xHYB Mycobacterium tuberculosis Panel at the upcoming ESCMID Global 2024 (formerly known as ECCMID), which will be held in Barcelona, Spain, from April 27 to April 30, 2024, at booth D20. Attendees can also join the Diagnostic Insights series, featuring insights from industry experts, and participate in demonstrations of diagnostic technology such as the QIAcuityDx digital PCR platform, QIAstat-Dx Analyzer 2.0, and QIAstat-Dx Rise. Additionally, a virtual reality demo of the QIAstat-Dx Rise will be available. For more information, please visit:
https://www.qiagen.com/us/applications/syndromic-testing/events-and-conferences/eccmid-inspiration
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of December 31, 2023, QIAGEN employed approximately 6,000 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations, markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of QIAGEN’s new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, and its impact on the demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.
Source: QIAGEN N.V.
Category: Corporate
[1] WHO Global Tuberculosis Report 2022, https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022/tb-disease-burden/2-3-drug-resistant-tb
Bay Street News
